Group B streptococcus and treatment of CAPD peritonitis.
Pagniez
D
D
Fruchart
A
A
Dequiedt
P
P
D000328:Adult; D002512:Cephalothin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000628:therapy; D006801:Humans; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology; D010878:Piperacillin / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013292:Streptococcus agalactiae
D002512:Cephalothin; D012293:Rifampin; D010878:Piperacillin